HC Wainwright & Co. Reiterates Buy on Eton Pharmaceuticals, Maintains $70 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Eton Pharmaceuticals (NASDAQ: ETON) and maintained a price target of $70 for the stock. No additional financial figures or strategic changes were mentioned in the article.